Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial
Study context
- Population
- Participants aged ≥50 years with baseline SBP 130–180 mm Hg at high cardiovascular (CV) risk (established CVD or 2 major CV risk factors)116 hospitals or primary care institutions
- Participants
- 11,255 participants
- Comparison
- Intensive vs standard blood pressure (BP) lowering strategy
- Primary endpoint
- Composite of:
- MI
- Coronary or non-coronary revascularization
- Hospitalization or ED visit for new-onset HF or acute decompensated HF
- Stroke
- CV death
Methodological detailsmulticentre, open-label, COVID-19 outbreak affected the BP lowering titration process and delayed the reach of BP target
- Multicentre
- Open-label
- COVID-19 outbreak affected the BP lowering titration process and delayed the reach of BP target
Primary result
As reported in the abstract
Baseline characteristics (no outcome results reported)
- Mean age (SD 7.1) years
- 64.6
- Women
- 4,650 (41.3%)
- CHD
- 28.9%
- Prior stroke
- 26.9%
- DM
- 38.7%
Original publication
Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial. Am Heart J. Published 7 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →